Jeffrey A. Lieberman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey A. Lieberman has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Robert A. Rosenheck
VA Connecticut Healthcare System
3 shared publications - Sonia M. Davis
A:Quintiles, Inc
3 shared publications - Thomas Scott Stroup
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York
3 shared publications - Diana O. Perkins
Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 shared publications - Jacob S. Ballon
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States
2 shared publications - John K. Hsiao
National Institute of Mental Health
2 shared publications
Latest Publications
- 30 January 2013
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 28 (2) , 183-187
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain
Background Previous studies have shown that antipsychotics with high propensity for antipsychotic‐induced weight gain (AIWG) influence glucose transporter type 4 (GLUT4) mediated glucose intake. Variation in the gene encoding TBC1 domain family member 1 (TBC1D1), a Rab‐GTPase activating protein regulating GLUT4 trafficking, has been associated with obesity. Therefore, we investigated the impact of TBC1D1 polymorphisms on AIWG. Methods We analyzed rs9852 and rs35859249 in TBC1D1 in 195 schizophrenia subjects treated mostly with clozapine or olanzapine for up to 14 weeks. Association was tested using analysis of variance and analysis of covariance with change (%) from baseline weight as the dependent variable. Results Analysis of covariance showed a non‐significant trend for lower weight gain in carriers of the T‐allele of rs9852 than in C‐allele homozygotes (p = 0.063). This effect was more pronounced in the subgroup of patients treated with clozapine or olanzapine (p = 0.024). For rs35859249, no significant association with AIWG could be detected. Conclusions This is the first study examining the association between TBC1D1 and AIWG. The moderate association of rs9852, located in the 3′UTR near a miRNA binding site, indicates an influence of TBC1D1 on AIWG. Further investigations remain necessary to elucidate the role of this gene in AIWG. Copyright © 2013 John Wiley & Sons, Ltd.
- 30 January 2013
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 28 (2) , 183-187
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain
Background Previous studies have shown that antipsychotics with high propensity for antipsychotic‐induced weight gain (AIWG) influence glucose transporter type 4 (GLUT4) mediated glucose intake. Variation in the gene encoding TBC1 domain family member 1 (TBC1D1), a Rab‐GTPase activating protein regulating GLUT4 trafficking, has been associated with obesity. Therefore, we investigated the impact of TBC1D1 polymorphisms on AIWG. Methods We analyzed rs9852 and rs35859249 in TBC1D1 in 195 schizophrenia subjects treated mostly with clozapine or olanzapine for up to 14 weeks. Association was tested using analysis of variance and analysis of covariance with change (%) from baseline weight as the dependent variable. Results Analysis of covariance showed a non‐significant trend for lower weight gain in carriers of the T‐allele of rs9852 than in C‐allele homozygotes (p = 0.063). This effect was more pronounced in the subgroup of patients treated with clozapine or olanzapine (p = 0.024). For rs35859249, no significant association with AIWG could be detected. Conclusions This is the first study examining the association between TBC1D1 and AIWG. The moderate association of rs9852, located in the 3′UTR near a miRNA binding site, indicates an influence of TBC1D1 on AIWG. Further investigations remain necessary to elucidate the role of this gene in AIWG. Copyright © 2013 John Wiley & Sons, Ltd.
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 2, 56
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)
Antipsychotic drugs are widely used in treating schizophrenia, bipolar disorder, and other psychiatric disorders. Many of these drugs, despite their therapeutic advantages, substantially increase body weight. We assessed the association of alleles of 31 genes implicated in body weight regulation with weight gain among patients being treated with specific antipsychotic medications in the clinical antipsychotic trials in intervention effectiveness study, we found that rs2237988 in Potassium Channel Inwardly Rectifying Subfamily J Member 11 (KCNJ11), rs13269119 in Solute carrier family 30 member 8 (SLC30A8), and rs9922047 in fat mass and obesity associated (FTO) were associated with percent weight gain. We also observed the significant interaction of rs11643744 by treatment effect on the weight gain.
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 2, 56
Open AccessAssociation of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)
Antipsychotic drugs are widely used in treating schizophrenia, bipolar disorder, and other psychiatric disorders. Many of these drugs, despite their therapeutic advantages, substantially increase body weight. We assessed the association of alleles of 31 genes implicated in body weight regulation with weight gain among patients being treated with specific antipsychotic medications in the clinical antipsychotic trials in intervention effectiveness study, we found that rs2237988 in Potassium Channel Inwardly Rectifying Subfamily J Member 11 (KCNJ11), rs13269119 in Solute carrier family 30 member 8 (SLC30A8), and rs9922047 in fat mass and obesity associated (FTO) were associated with percent weight gain. We also observed the significant interaction of rs11643744 by treatment effect on the weight gain.
- 1 August 2010
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 31 (8) , 381-390
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
- 1 August 2010
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 31 (8) , 381-390
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
- 1 January 2010
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 8 (4) , 475-487
Advances in the Management of Treatment- Resistant Schizophrenia
- 1 January 2010
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 8 (4) , 475-487
Advances in the Management of Treatment- Resistant Schizophrenia
- 22 December 2009
- Published by Cambridge University Press (CUP)
Preface to the fourth edition
This is a major international textbook for psychiatrists and other professionals working in the field of mental healthcare. With contributions from opinion-leaders from around the globe, this book will appeal to those in training as well as to those further along the career path seeking a comprehensive and up-to-date overview of effective clinical practice backed by research evidence. The book is divided into cohesive sections moving from coverage of the tools and skills of the trade, through descriptions of the major psychiatric disorders and on to consider special topics and issues surrounding service organization. The final important section provides a comprehensive review of treatments covering all of the major modalities. Previously established as the Essentials of Postgraduate Psychiatry, this new and completely revised edition is the only book to provide this depth and breadth of coverage in an accessible, yet authoritative manner.
- 22 December 2009
- Published by Cambridge University Press (CUP)
Preface to the fourth edition
This is a major international textbook for psychiatrists and other professionals working in the field of mental healthcare. With contributions from opinion-leaders from around the globe, this book will appeal to those in training as well as to those further along the career path seeking a comprehensive and up-to-date overview of effective clinical practice backed by research evidence. The book is divided into cohesive sections moving from coverage of the tools and skills of the trade, through descriptions of the major psychiatric disorders and on to consider special topics and issues surrounding service organization. The final important section provides a comprehensive review of treatments covering all of the major modalities. Previously established as the Essentials of Postgraduate Psychiatry, this new and completely revised edition is the only book to provide this depth and breadth of coverage in an accessible, yet authoritative manner.
- 1 October 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 105 (1-3) , 175-187
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
- 1 October 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 105 (1-3) , 175-187
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
- 18 September 2008
- Published by Cambridge University Press (CUP)
- p. 586-621
Biological treatments for psychotic disorders
This chapter describes the psychiatric disorders of old age such as dementia, delirium, neurosis and suicide. It discusses the epidemiology, aetiology, course and outcome, and the management and treatment of various psychiatric disorders of old age. The needs of older people with mental health problems are not confined simply to mental health but also physical health and social care needs. Alzheimer's disease (AD) has been reported as consistently more common than vascular dementia in studies in developed countries. Genetic abnormalities have been shown to be risk factors for dementia. A medical history should be taken with particular relevance to risk factors for cardiovascular or cerebrovascular disease and a history of transient ischaemic attacks. The clinical management of a person with dementia is considered under three main headings: general care and support; treatment of cognitive symptoms; and management of behavioural and psychological symptoms.
- 18 September 2008
- Published by Cambridge University Press (CUP)
- p. 586-621
Biological treatments for psychotic disorders
This chapter describes the psychiatric disorders of old age such as dementia, delirium, neurosis and suicide. It discusses the epidemiology, aetiology, course and outcome, and the management and treatment of various psychiatric disorders of old age. The needs of older people with mental health problems are not confined simply to mental health but also physical health and social care needs. Alzheimer's disease (AD) has been reported as consistently more common than vascular dementia in studies in developed countries. Genetic abnormalities have been shown to be risk factors for dementia. A medical history should be taken with particular relevance to risk factors for cardiovascular or cerebrovascular disease and a history of transient ischaemic attacks. The clinical management of a person with dementia is considered under three main headings: general care and support; treatment of cognitive symptoms; and management of behavioural and psychological symptoms.
- 1 April 2007
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 7 (2) , 103-111
Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial
The cost–effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300–600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
- 1 April 2007
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 7 (2) , 103-111
Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial
The cost–effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300–600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
- 15 June 2006
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 67 (06) , 983-990
Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection
- 15 June 2006
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 67 (06) , 983-990
Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection